CELL AND GENE THERAPY INSIGHTS

Exploring key regulatory considerations to ensure patient safety in the gene therapy space

Exploring key regulatory considerations to ensure patient safety in the gene therapy space

L Shaw, C Le Bec, M Orio et al
01 July 2025
Register
Actionable insights for overcoming CMC challenges in TIL therapy: GRIT’s strategic approach

Actionable insights for overcoming CMC challenges in TIL therapy: GRIT’s strategic approach

Alex Lei
19 June 2025
Register
How do I ensure my early-stage analytical development is ‘phase-appropriate’? Top 5 tips: INFOGRAPHIC

How do I ensure my early-stage analytical development is ‘phase-appropriate’? Top 5 tips: INFOGRAPHIC

03 June 2025
Infographic
A structured approach to addressing leachable risk in cell and gene therapies

A structured approach to addressing leachable risk in cell and gene therapies

Jason Creasey
24 April 2025
Expert Insight
Optimizing iPSC therapies: strategies for safe, cost-effective, and scalable manufacturing

Optimizing iPSC therapies: strategies for safe, cost-effective, and scalable manufacturing

K Bruce, K Bharti, I Barbaric et al
23 April 2025
Watch
A path toward universal agreement on fulfilling the need for rapid and reliable sterility assays in gene therapy

A path toward universal agreement on fulfilling the need for rapid and reliable sterility assays in gene therapy

Qin Xiang
14 April 2025
Viewpoint
Navigating analytical and regulatory hurdles in early-phase clinical cell therapy development

Navigating analytical and regulatory hurdles in early-phase clinical cell therapy development

Vaibhav Patel
10 April 2025
Interview
Conducting rapid microbiological monitoring in fill-finish with biofluorescent particle counters: a collaborative case study

Conducting rapid microbiological monitoring in fill-finish with biofluorescent particle counters: a collaborative case study

M Dingle, A Carwell, M J. Miller et al
08 April 2025
Watch
Advancing quality standards for gene therapies: a USP perspective

Advancing quality standards for gene therapies: a USP perspective

Fouad Atouf
08 April 2025
Interview
CAR-T manufacturing intensification: the next wave of CAR-T commercialization

CAR-T manufacturing intensification: the next wave of CAR-T commercialization

A Bersenev, E Kleiren, J Knighton et al
03 April 2025
Innovator Insight
Advancing optogenetic therapies for retinal diseases: a regulatory vision

Advancing optogenetic therapies for retinal diseases: a regulatory vision

Ananta Ayyagari
24 March 2025
Interview
Ensuring compliance through collaboration: managing raw material changes in cell and gene therapy regulatory filings

Ensuring compliance through collaboration: managing raw material changes in cell and gene therapy regulatory filings

Kasey Kime, Xiao Peng
20 March 2025
Innovator Insight
Streamlining the supply chain: insights on raw material sourcing and quality by design

Streamlining the supply chain: insights on raw material sourcing and quality by design

Lara Silverman
19 March 2025
Interview
GMP or not? Understanding raw material quality grades and requirements for ATMP manufacturing

GMP or not? Understanding raw material quality grades and requirements for ATMP manufacturing

Lili Belcastro, Basak Clements, Claire Wartel
18 March 2025
Watch
Raw and starting materials for cellular and gene therapy products

Raw and starting materials for cellular and gene therapy products

Gary du Moulin
04 March 2025
Review
Worth the switch? Enhancing process performance for cell therapy manufacturing with an animal component-free raw material strategy

Worth the switch? Enhancing process performance for cell therapy manufacturing with an animal component-free raw material strategy

Phil Morton, Shanya Jiang
03 March 2025
Innovator Insight
Modernizing viral clearance study strategy: regulatory updates and industry best practices

Modernizing viral clearance study strategy: regulatory updates and industry best practices

Audrey Chang, Kathleen Kenney
25 February 2025
Watch
Regulatory innovations: why is the UK an attractive hub for CGT development?

Regulatory innovations: why is the UK an attractive hub for CGT development?

Rehma Chandaria
13 February 2025
Interview
Early-stage analytical development strategies for cell therapy

Early-stage analytical development strategies for cell therapy

Ramon Mendoza, Kyle Carter, Seth Peterson
16 January 2025
Expert Roundtable
‘Winning’ target product profiles for CAR-T cell therapies in oncology: critical success factors for commercially viable therapies

‘Winning’ target product profiles for CAR-T cell therapies in oncology: critical success factors for commercially viable therapies

Clare Hague, Louise Street-Docherty, Frances Pearson
19 December 2024
Expert Insight
From concept to clinic: overcoming the challenges of potency assays in cell and gene therapy development

From concept to clinic: overcoming the challenges of potency assays in cell and gene therapy development

Audrey Chang, Joe Newcome
10 December 2024
Watch